| Literature DB >> 28558668 |
Young Woon Chang1, Chi Hyuk Oh1, Jung-Wook Kim2, Jae Won Lee3, Mi Ju Park3, Jae-Jun Shim1, Chang Kyun Lee1, Jae-Young Jang1, Seok Ho Dong1, Hyo Jong Kim1, Sung Soo Kim4, Byung-Ho Kim1.
Abstract
BACKGROUND: Mannose-binding lectin (MBL) acts in the innate immune response to Helicobacter pylori. Interleukin 8 (IL-8) is a potent cytokine produced by gastric epithelial cells in response to H. pylori. We aimed to investigate whether polymorphisms in MBL2 and IL-8 influence susceptibility to H. pylori infection, and the associations of these polymorphisms with the risk of gastroduodenal diseases in a Korean population.Entities:
Keywords: Gastric cancer; Helicobacter pylori; Interleukin 8; Mannose-binding lectin 2
Mesh:
Substances:
Year: 2017 PMID: 28558668 PMCID: PMC5450387 DOI: 10.1186/s12885-017-3378-2
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Basic clinical features of the control and disease groups
| Hp (−) | Hp (+) | Hp (+) | Hp (+) | DU | GC |
| |
|---|---|---|---|---|---|---|---|
| Sex (M:F) | 87:89 | 41:67 | 23:29 | 37:24 | 90:85 | 151:132 | 0.1832a |
| Mean age (years) | 52.5 ± 6.7 | 51.58 ± 6.65 | 59.52 ± 8.30 | 60.89 ± 8.55 | 53.2 ± 12.6 | 55.5 ± 8.8 | 0.1431b |
| Alcohol consumption (%) | 52.27% | 51.85% | 48.46% | 47.54% | 57.71% | 55.48% | 0.1751a |
| Smoking habits (%) | 19.89% | 18.52% | 30.77% | 26.23% | 58.86% | 40.99% | <0.0001a |
| High salt intake (%) | 25.00% | 26.85% | 16.92% | 49.18 | 39.43% | 48.41% | <0.0001a |
| FHx of GC (%) | 10.23% | 15.52% | 13.79% | 16.39% | 10.86% | 20.85% | 0.0043a |
| Hp positivity (%) | 0% | 100% | 100% | 100% | 96.00% | 73.14% | <0.0001a |
a: Chi square test for comparison of percentage (GC vs control)
b: Kruskal-Wallis test for comparison of mean ± SD (GC vs control)
The frequencies of MBL2 codon 54 and IL-8 -251 genotypes in the control and disease groups
| Genotype | Control | Hp (+) | Hp (+) | Hp (+) | Hp (−) | Hp (+) | Hp (−) | Hp (+) | |
|---|---|---|---|---|---|---|---|---|---|
|
| G/G (wild type) | 103 (58.52) | 65 (60.19) | 29 (55.77) | 32 (52.46) | 4 (57.14) | 95 (56.55) | 41 (53.95) | 129 (62.32) |
| G/A(heterozygote) | 63 (35.80) | 37 (34.26) | 22 (43.31) | 27 (44.26) | 3 (42.86) | 69 (41.07) | 29 (32.37) | 67 (32.37) | |
| A/A (mutant) | 10 (5.68) | 6 (5.56) | 1 (1.92) | 2 (3.28) | 0 (0.00) | 4 (2.38) | 6 (5.31) | 11 (5.31) | |
| G/A + A/A (A carrier) | 73 (41.48) | 43 (39.81) | 23 (44.23) | 29 (47.54) | 4 (57.14) | 73 (43.45) | 35 (46.05) | 78 (37.68) | |
|
| T/T (wild type) | 70 (39.77) | 52 (48.15) | 20 (38.46) | 15 (24.59) | 3 (42.86) | 81 (48.21) | 23 (30.26) | 58 (28.02) |
| T/A (heterozygote) | 89 (50.57) | 49 (45.37) | 27 (51.92) | 37 (60.66) | 3 (42.86) | 73 (43.45) | 46 (60.53) | 122 (58.94) | |
| A/A (mutant) | 17 (9.66) | 7 (6,48) | 5 (9.62) | 9 (16.75) | 1 (14.29) | 14 (8.33) | 7 (9.21) | 27 (13.04) | |
| T/A + A/A (A carrier) | 106 (60.23) | 56 (51.85) | 32 (61.54) | 46 (75.41) | 4 (57.14) | 87 (51.79) | 53 (69.74) | 149 (71.99) | |
The frequencies of MBL2 codon 54 and IL-8 -251 genotypes were not significantly different between the control and disease groups
MBL codon 54 G > A polymorphism and the risk of gastroduodenal diseases
| Genotype | Disease group | Unadjusted OR (95% CI) by univariate analysis |
| Adjusted OR (95% CI) by multivariate analysis |
|
|---|---|---|---|---|---|
| G/A (heterozygote) | Hp(+) NAG ( | 0.93 (0.56–1.55) | 0.7828 | 1.02 (0.59–1.75) | 0.9466 |
| Hp(+) mild AG ( | 1.24 (0.66–2.34) | 0.5074 | 1.16 (0.60–2.26) | 0.6527 | |
| Hp(+) severe AG ( | 1.38 (0.76–2.52) | 0.2937 | 1.16 (0.61–2.18) | 0.6498 | |
| Hp(−) DU( | 1.23 (0.27–5.66) | 0.7938 | 1.21 (0.26–5.71) | 0.8082 | |
| Hp(+) DU ( | 1.19 (0.76–1.85) | 0.4450 | 1.24 (0.78–1.99) | 0.3605 | |
| Hp(−) GC( | 1.16 (0.65–2.04) | 0.6170 | 1.11 (0.61–2.00) | 0.7356 | |
| Hp(+) GC ( | 0.85 (0.55–1.31) | 0.4566 | 0.85 (0.54–1.34) | 0.7356 | |
| A/A (mutant) | Hp(+) NAG ( | 0.95 (0.33–2.74) | 0.9255 | 1.19 (0.39–3.61) | 0.7561 |
| Hp(+) mild AG ( | 0.36 (0.04–2.89) | 0.3332 | 0.33 (0.04–2.81) | 0.3126 | |
| Hp(+) severe AG ( | 0.64 (0.13–3.09) | 0.5822 | 0.61 (0.12–3.12) | 0.5560 | |
| Hp(−) DU ( | 1.25(0.32–5.88) | 0.9521 | 1.24(0.31–5.77) | 0.9434 | |
| Hp(+) DU ( | 0.43 (0.13–1.43) | 0.1697 | 0.45 (0.13–1.55) | 0.2031 | |
| Hp(−) GC ( | 1.51 (0.52–4.42) | 0.4543 | 1.93 (0.63–5.89) | 0.2484 | |
| Hp(+) GC ( | 0.88 (0.36–2.15) | 0.7762 | 1.10 (0.43–2.79) | 0.8496 | |
| G/A + A/A (A carrier) |
| 0.93 (0.57–1.52) | 0.7820 | 1.04 (0.62–1.75) | 0.8774 |
| Hp(+) mild AG ( | 1.12 (0.60–2.09) | 0.7239 | 1.05 (0.55–2.00) | 0.8893 | |
| Hp(+) severe AG ( | 1.28 (0.71–2.29) | 0.4103 | 1.09 (0.59–2.01) | 0.7929 | |
| Hp(−) DU ( | 1.06 (0.23–4.87) | 0.9421 | 1.06 (0.23–4.98) | 0.9386 | |
| Hp(+) DU ( | 1.08 (0.71–1.66) | 0.7110 | 1.13 (0.72–1.78) | 0.5868 | |
| Hp(−) GC ( | 1.20 (0.70–2.07) | 0.5008 | 1.19 (0.68–2.09) | 0.5480 | |
| Hp(+) GC ( | 0.85 (0.57–1.29) | 0.4488 | 0.88 (0.57–1.35) | 0.5528 |
The control was regarded as the reference subject group, and the G/G wild type was considered as the reference genotype
Fig. 1Serum MBL levels in all subjects according to MBL2 codon 54 genotype. Serum MBL levels differed significantly between the three genotypes, as determined by the Kruskal–Wallis test (p < 0.0001)
IL-8 -251 T > A polymorphism and the risk of gastroduodenal diseases
| Genotype | Disease group | Unadjusted OR (95% CI) by univariate analysis |
| Adjusted OR (95% CI) by multivariate analysis |
|
|---|---|---|---|---|---|
| T/A (heterozygote) | Hp(+) NAG ( | 0.74 (0.45–1.22) | 0.2406 | 0.76 (0.46–1.29) | 0.3018 |
| Hp(+) mild AG ( | 1.06 (0.55–2.05) | 0.8581 | 1.09 (0.55–2.16) | 0.8052 | |
| Hp(+) severe AG ( | 1.94 (0.99–3.82) | 0.0549 | 2.06 (1.01–4.21) | 0.0471 | |
| Hp(−) DU( | 0.79 (0.15–4.02) | 0.7729 | 0.84 (0.16–4.36) | 0.8342 | |
| Hp(+) DU ( | 0.71 (0.45–1.11) | 0.1297 | 0.80 (0.50–1.29) | 0.3616 | |
| Hp(−) GC( | 1.57 (0.87–2.84) | 0.1326 | 1.66 (0.89–3.07) | 0.1058 | |
| Hp(+) GC ( | 1.65 (1.06–2.58) | 0.0257 | 1.71 (1.07–2.72) | 0.0252 | |
| A/A (mutant) | Hp(+) NAG ( | 0.55 (0.21–1.43) | 0.2237 | 0.59 (0.21–1.59) | 0.2952 |
| Hp(+) mild AG ( | 1.03 (0.34–3.14) | 0.9593 | 1.00 (0.31–3.17) | 0.9941 | |
| Hp(+) severe AG ( | 2.47 (0.93–6.59) | 0.0710 | 2.42 (0.85–6.84) | 0.0966 | |
| Hp(−) DU ( | 1.37 (0.13–14.03) | 0.7895 | 1.66 (0.16–17.71) | 0.6743 | |
| Hp(+) DU ( | 0.71 (0.33–1.55) | 0.3905 | 0.72 (0.32–1.63) | 0.4289 | |
| Hp(−) GC ( | 1.25 (0.46–3.40) | 0.6577 | 1.19 (0.43–3.34) | 0.7403 | |
| Hp(+) GC ( | 1.92 (0.95–3.86) | 0.0683 | 1.94 (0.93–4.06) | 0.0744 | |
| T/A + A/A | Hp(+) NAG ( | 0.71 (0.44–1.15) | 0.1669 | 0.73 (0.44–1.22) | 0.2282 |
| Hp(+) mild AG ( | 1.06 (0.56–1.99) | 0.8651 | 1.07 (0.55–2.08) | 0.8336 | |
| Hp(+) severe AG ( | 2.03 (1.05–3.90) | 0.0351 | 2.12 (1.06–4.25) | 0.0335 | |
| Hp(−) DU ( | 0.88 (0.19–4.05) | 0.8703 | 0.96 (0.20–4.48) | 0.3066 | |
| Hp(+) DU ( | 0.71 (0.46–1.09) | 0.1152 | 0.79 (0.50–1.24) | 0.3035 | |
| Hp(−) GC ( | 1.52 (0.86–2.70) | 0.1524 | 1.58 (0.87–2.87) | 0.1346 | |
| Hp(+) GC ( | 1.70 (1.11–2.60) | 0.0155 | 1.74 (1.11–2.74) | 0.0161 |
The control was regarded as the reference subject group, and the T/T wild type was considered as the reference genotype
Fig. 2IL-8 levels in all H. pylori-positive subjects according to IL-8 -251 genotype. IL-8 levels differed significantly between the three genotypes, as determined by the Kruskal–Wallis test (p = 0.0262)
Fig. 3IL-8 levels according to disease phenotypes and IL-8 -251 genotype. The disease groups did not show any significant differences in IL-8 levels between the T/T, T/A, and A/A genotypes or for A allele carriers, as determined by multiple group comparison test. However, H. pylori-positive GC A allele carriers showed significantly higher IL-8 levels than NAG A allele carriers (p = 0.0229), as determined by two group comparison test
The association of IL-8 -251 T > A polymorphism with the risk of GC in different ethnicities
| Ethnicity | TT / total GC (%) | TA / total GC (%) | AA / total GC (%) | A* / total GC (%) |
|---|---|---|---|---|
| This study | 81/283 (28.62%) | 168/283(59.36%) | 34/283(12.01%) | 202/283(71.38%) |
| Korean | 180/487(36.96%) | 241/487(49.49%) | 66/487(13.55%) | 307/487(63.04%) |
| Japanese | 337/789(42.71%) | 375/789(47.53%) | 77/789(9.76%) | 452/789(57.29%) |
| Chinese | 329/926(35.53%) | 425/926(45.90%) | 172/926(18.57%) | 597/926(64.47%) |
| Caucasian | 224/732(30.60%) | 365/732(49.86%) | 143/732(19.54%) | 508/732(69.40%) |
| Combined | 598/1559(38.36%) | 784/1559(50.29%) | 177/1559(11.35%) | 961/1559(61.64%) |
A*: A allele carriers (T/A + A/A)
The combined Korean and Japanese populations showed significant GC risk in IL-8 -251 T/A, A/A, and A allele carriers